Immunological alterations in patients with chronic prostatitis/chronic pelvic pain syndrome and experimental autoimmune prostatitis model: A systematic review and meta-analysis
Immunological alterations in patients with chronic prostatitis/chronic pelvic pain syndrome and experimental autoimmune prostatitis model: A systematic review and meta-analysis
复制标题
慢性前列腺炎/慢性盆腔疼痛综合征和实验性自身免疫性前列腺炎模型患者的免疫学改变:系统评价和荟萃分析。
DOI:
10.1016/j.cyto.2021.155440
复制
发表时间:
2021-02-04
期刊:
影响因子:
3.8
通讯作者:
Liang, Chaozhao
中科院分区:
文献类型:
--
作者:
Chen, Lei;Bian, Zichen;Liang, Chaozhao
Background: As one of the most common conditions in urological outpatients, chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) puzzles many individuals because of its unclear etiology and lack of effective treat-ment. Recently, immunological alterations underpinning CP/CPPS have been extensively investigated. Methods: The PubMed, Web of Science, Cochrane library, and EMBASE databases were used to search original articles on immune mediators in patients with CP/CPPS and in experimental autoimmune prostatitis (EAP) models through April 10, 2020. Standardized mean differences (SMD) were calculated to summarize the dif-ferences in immune mediator levels between groups. Funnel plot, Begg?s funnel plot, Egger?s regression test, and the sensitivity analysis were applied to determine and visualize the stability of our findings. Results: A total of 34 original studies were included in the meta-analysis, including 24 studies on patients with CP/CPPS and 10 studies on EAP models. We found that TNF-?, IL-1?, IL-6, and IL-8 were the four immune mediators that elevated in most of the samples derived from patients with CP/CPPS and the EAP models. The adjusted publication bias analysis indicated that publication bias was not existed, and the sensitivity analyses showed that the results were stable. Conclusions: Immune responses play significant roles during the pathogenesis of CP/CPPS by promoting intra-prostatic inflammation. Our findings provide potential diagnostic and therapeutic targets for CP/CPPS patients.